

08 September 2022

Biological Treatments for Rheumatology

Request

We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV 55	subcut 158
• Adalimumab [Humira]	415	
• Adalimumab Biosimilars	675	
• Apremilast [Otezla]	34	
• Baricitinib [Olumiant]	53	
• Certolizumab [Cimzia]	113	
• Etanercept [Enbrel]	135	
• Etanercept Biosimilars	347	
• Filgotinib [Jyseleca]	<5	
• Golimumab [Simponi]	101	
• Guselkumab [Tremfya]	6	
• Infliximab [Remicade]	IV 52	subcut <5
• Infliximab Biosimilars	50	
• Ixekizumab [Taltz]	76	
• Risankizumab [Skyrizi]	<5	
• Rituximab [MabThera]	90	
• Rituximab Biosimilars	241	
• Sarilumab [Kevzara]	5	
• Secukinumab [Cosentyx]	214	
• Tocilizumab [Ro Actemra]	IV 50	subcut 136
• Tofacitinib [Xeljanz]	29	
• Upadacitinib [Rinvoq]	65	
• Ustekinumab [Stelara]	19	